These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22052988)

  • 1. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'.
    Mandala M; Clerici M; Corradino I; Vitalini C; Colombini S; Torri V; De Pascale A; Marsoni S
    Ann Oncol; 2012 Jun; 23(6):1416-21. PubMed ID: 22052988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies.
    Mandalà M; Grosso F; Vitalini C; Corradino I; Sanfilippo R; Colombini S; Clerici M; Labianca R; De Pascale A; Marsoni S
    Br J Cancer; 2012 Aug; 107(4):612-6. PubMed ID: 22828607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study.
    Kruger S; Haas M; Burkl C; Goehring P; Kleespies A; Roeder F; Gallmeier E; Ormanns S; Westphalen CB; Heinemann V; Rank A; Boeck S
    Thromb Res; 2017 Sep; 157():9-15. PubMed ID: 28675831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy.
    Ramos JD; Casey MF; Bamias A; De Giorgi U; Bellmunt J; Harshman LC; Ladoire S; Wong YN; Alva AS; Rosenberg JE; Galsky MD; Yu EY;
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):755-760. PubMed ID: 27637910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of Khorana Risk Score for Prediction of Venous Thromboembolism in Patients With Hepatocellular Carcinoma.
    Wang Y; Attar BM; Fuentes HE; Yu J; Zhang H; Tafur AJ
    Clin Appl Thromb Hemost; 2018 Apr; 24(3):471-476. PubMed ID: 28288526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venous Thromboembolism Is an Independent Predictor of Mortality Among Patients with Gastric Cancer.
    Fuentes HE; Oramas DM; Paz LH; Wang Y; Andrade XA; Tafur AJ
    J Gastrointest Cancer; 2018 Dec; 49(4):415-421. PubMed ID: 28634671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality.
    Kuderer NM; Culakova E; Lyman GH; Francis C; Falanga A; Khorana AA
    Oncologist; 2016 Jul; 21(7):861-7. PubMed ID: 27125754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana Risk Score.
    Rupa-Matysek J; Gil L; Kaźmierczak M; Barańska M; Komarnicki M
    Med Oncol; 2017 Dec; 35(1):5. PubMed ID: 29209847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of Venous Thromboembolism in cancer patients treated with Cisplatin based chemotherapy - a cohort study.
    Zahir MN; Shaikh Q; Shabbir-Moosajee M; Jabbar AA
    BMC Cancer; 2017 Jan; 17(1):57. PubMed ID: 28093087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Predicting the Incidence of Venous Thromboembolism Using the Khorana Score: A Literature Review].
    Nishimura A; Ikeda Y
    Yakugaku Zasshi; 2021; 141(4):611-622. PubMed ID: 33790126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer.
    Mansfield AS; Tafur AJ; Wang CE; Kourelis TV; Wysokinska EM; Yang P
    J Thromb Haemost; 2016 Sep; 14(9):1773-8. PubMed ID: 27273134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of glycemic parameters on venous thromboembolism risk prediction in gastrointestinal cancer.
    Guadagni F; Riondino S; Formica V; Del Monte G; Morelli AM; Lucchetti J; Spila A; D'Alessandro R; Della-Morte D; Ferroni P; Roselli M
    World J Gastroenterol; 2017 Jul; 23(28):5187-5195. PubMed ID: 28811713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.
    Moik F; Chan WE; Wiedemann S; Hoeller C; Tuchmann F; Aretin MB; Fuereder T; Zöchbauer-Müller S; Preusser M; Pabinger I; Ay C
    Blood; 2021 Mar; 137(12):1669-1678. PubMed ID: 33067632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes.
    Frere C; Bournet B; Gourgou S; Fraisse J; Canivet C; Connors JM; Buscail L; Farge D;
    Gastroenterology; 2020 Apr; 158(5):1346-1358.e4. PubMed ID: 31843588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CK-RAM study.
    Abdel-Razeq H; Sharaf B; Al-Jaghbeer MJ; Abu-Fares H; Bater R; Shaer MA; Abu-Jaish H; Laban DA; Salamah O; Tamimi F; Ashouri K; Salameh T; Zughul R; Alhalaseh Y
    J Thromb Thrombolysis; 2023 Oct; 56(3):447-453. PubMed ID: 37430158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL).
    Santi RM; Ceccarelli M; Catania G; Monagheddu C; Evangelista A; Bernocco E; Monaco F; Federico M; Vitolo U; Cortelazzo S; Cabras MG; Spina M; Baldini L; Boccomini C; Chiappella A; Bari A; Luminari S; Calabrese M; Levis A; Visco C; Contino L; Ciccone G; Ladetto M
    Thromb Res; 2016 Apr; 140 Suppl 1():S177. PubMed ID: 27161692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience.
    Vemulapalli S; Chintala L; Tsimberidou AM; Dhillon N; Lei X; Hong D; Kurzrock R
    Am J Hematol; 2009 Jul; 84(7):408-13. PubMed ID: 19437507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer.
    Vergati M; Della-Morte D; Ferroni P; Cereda V; Tosetto L; La Farina F; Guadagni F; Roselli M
    Rejuvenation Res; 2013 Jun; 16(3):224-31. PubMed ID: 23521603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings.
    Mandalà M; Barni S; Floriani I; Isa L; Fornarini G; Marangolo M; Mosconi S; Corsi D; Rulli E; Frontini L; Cortesi E; Zaniboni A; Aglietta M; Labianca R
    Eur J Cancer; 2009 Jan; 45(1):65-73. PubMed ID: 19068274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of type 2 diabetes mellitus on Khorana venous thromboembolism risk in colorectal cancer patients.
    Wang R; Liu R; Zhao L; Xu D; Hu L
    Rev Esp Enferm Dig; 2017 Jul; 109(7):503-509. PubMed ID: 28593781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.